



Fund Details

Investment Objective

The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes' objectives will be achieved.

Fund Category

Thematic (Equity)

Investment Style

Large Cap			
Mid Cap			
Small Cap			
	Growth	Value	Blend



Fund Manager

Mr. Dhaval Shah & Mr. Dhaval Joshi

Date of Allotment

July 11, 2019

Benchmark

S&P BSE Healthcare TRI

Managing Fund Since

July 11, 2019 & November 21, 2022

Experience in Managing the Fund

4.8 Years & 1.4 Years

SIP

Daily/Weekly/Monthly: Minimum ₹ 100/-

Load Structure (as % of NAV) (Incl. for SIP)

Entry Load	Nil
Exit Load	For redemption/switchout of units on or before 30 days from the date of allotment: 1.00% of applicable NAV. For redemption/switch-out of units after 30 days from the date of allotment: Nil

AUM

Monthly Average AUM	₹	688.73	Crores
AUM as on last day	₹	699.55	Crores

Total Expense Ratio (TER)

Regular	2.37%
Direct	1.02%

Including additional expenses and goods and service tax on management fees.

Other Parameters

Standard Deviation	15.44%
Sharpe Ratio	0.65
Beta	0.94
Portfolio Turnover	0.33

Note: Standard Deviation, Sharpe Ratio & Beta are calculated on Annualised basis using 3 years history of monthly returns. Risk Free Rate assumed to be 7.90% (FBIL Overnight MIBOR as on 31 March 2024) for calculating Sharpe Ratio

Application Amount for fresh subscription

₹ 1,000 (plus in multiples of ₹ 1)

Min. Addl. Investment

₹ 1,000 (plus in multiples of ₹ 1)

PORTFOLIO

Issuer	% to Net Assets
Pharmaceuticals & Biotechnology	73.80%
Sun Pharmaceutical Industries Limited	15.74%
Cipla Limited	8.31%
Torrent Pharmaceuticals Limited	7.24%
Zydus Lifesciences Limited	4.46%
Ajanta Pharmaceuticals Limited	4.16%
Lupin Limited	3.80%
Gland Pharma Limited	3.59%
Alkem Laboratories Limited	3.52%
ALEMBIC PHARMACEUTICALS LIMITED	3.38%
Abbott India Limited	3.10%
J.B. Chemicals & Pharmaceuticals Limited	2.90%
Dr. Reddys Laboratories Limited	2.80%
Sanofi India Limited	2.66%
Strides Pharma Science Limited	2.28%
Aurobindo Pharma Limited	2.12%
Mankind Pharma Ltd	1.47%
Granules India Limited	0.91%

Issuer	% to Net Assets
Eris Lifesciences Limited	0.80%
Biocon Limited	0.56%
Healthcare Services	15.35%
Apollo Hospitals Enterprise Limited	6.72%
Fortis Healthcare Limited	4.37%
Jupiter Life Line Hospitals Ltd	2.25%
Vijaya Diagnostic Centre Limited	2.01%
Insurance	2.94%
Star Health & Allied Insurance Limited	1.90%
Medi Assist Healthcare Services Ltd	1.04%
Retailing	0.56%
Medplus Health Services Limited	0.56%
Chemicals & Petrochemicals	0.40%
Vinati Organics Limited	0.40%
Cash & Current Assets	6.96%
Total Net Assets	100.00%

Investment Performance

NAV as on March 31, 2024: ₹ 26.4500

Inception - July 11, 2019	Since Inception	5 Years	3 Years	1 Year
Aditya Birla Sun Life Pharma & Healthcare Fund	22.84%	NA	17.93%	61.46%
Value of Std Investment of ₹ 10,000	26450	NA	16408	16167
Benchmark - S&P BSE Healthcare TRI	24.81%	NA	18.82%	61.70%
Value of Std Investment of ₹ 10,000	28470	NA	16761	16127
Additional Benchmark - Nifty 50 TRI	16.42%	NA	16.35%	30.27%
Value of Std Investment of ₹ 10,000	20497	NA	15736	13008

Past performance may or may not be sustained in future. The above performance is of Regular Plan - Growth Option. Kindly note that different plans have different expense structure. Load and Taxes are not considered for computation of returns. When scheme/additional benchmark returns are not available, they have not been shown. Total Schemes Co-Managed by Fund Managers is 1. Total Schemes managed by Mr. Dhaval Shah is 8. Total Schemes managed by Mr. Dhaval Joshi is 51.

Note: The exit load (if any) rate levied at the time of redemption/switch-out of units will be the rate prevailing at the time of allotment of the corresponding units. Customers may request for a separate Exit Load Applicability Report by calling our toll free numbers 1800-270-7000 or from any of our Investor Service Centers.

NAV of Plans / Options (₹)

	Regular Plan	Direct Plan
Growth	26.4500	28.5400
IDCW ² :	19.9800	21.2300

²Income Distribution cum capital withdrawal



SIP Performance - Regular Plan - Growth (assuming SIP of ₹ 10000 per month)

Particulars	Since Inception	5 years	3 years	1 Year
Total Amount Invested (₹)	570000	NA	360000	120000
Market Value of amount Invested	968766	NA	511364	155138
Scheme Returns (CAGR)	22.67%	NA	24.32%	59.56%
S&P BSE Healthcare TRI# (CAGR)	24.09%	NA	24.20%	56.86%
Nifty 50 TRI## (CAGR)	19.06%	NA	16.88%	27.81%

Past Performance may or may not be sustained in future. The Fund's inception date is July 11, 2019, and the initial SIP installment is considered to have been made on that date. Subsequent installments occur on the first day of every following month.


Scheme Benchmark, ## Additional Benchmark

For SIP calculations above, the data assumes the investment of ₹ 10000/- on 1st day of every month or the subsequent working day. Load & Taxes are not considered for computation of returns. Performance for IDCW option would assume reinvestment of tax free IDCW declared at the then prevailing NAV. CAGR returns are computed after accounting for the cash flow by using XIRR method (investment internal rate of return). Where Benchmark returns are not available, they have not been shown. Past performance may or may not be sustained in future. Returns greater than 1 year period are compounded annualized. IDCW are assumed to be reinvested and bonus is adjusted. Load is not taken into consideration.

Product Labeling Disclosures

Aditya Birla Sun Life Pharma & Healthcare Fund
(An Open Ended equity scheme investing in Pharma and Healthcare Services Sector)

- Long term capital growth
- Investments in equity & equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India



*Investors should consult their financial advisors if in doubt whether the product is suitable for them.

